Authors: M. Zeman 1; A. Žák 2 Authors‘ workplace: IV. interní klinika 1. LF UK a VFN, Praha 2Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK a VFN, Praha 1 Published in: Čas. Lék. čes. 2004; : 302-306 Category:
Patients with type 2 diabetes mellitus are at the higher risk of development of on arteriosclerosis based cardiovasculardiseases. Epidemiological studies have shown that diabetic dislipidemiawith hypertriglyceridemia, presence of smalldense LDL subfraction, low concentration of HDL-cholesterol and increased postprandial lipemia can representa serious threat. Several studies have found significant decrease of cardiovascular morbidity and mortality aftera treatment of diabetic dislipidemia, namely by statins and fibrates. Contemporary therapeutic algorhithms ofEuropean and American professional societies for the hyperlipidemia treatment classify diabetes mellitus as anequivalent of already developed complication of atherosclerosis. Our article presents pathophysiology of the diabeticdislipidemia, recommended target values of pasma lipids in diabetic patients and an overview of present possibilitiesof pharmacotherapy of the diabetic dislipidemia.
Key words: diabetic dislipidemia, cardiovascular diseases, statins, fibrates, combination therapy of hypolipidemia,polyenic fatty acids.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
